Background: Evidence from animal and human studies suggests a protective effect of higher water intake on kidney function and cardiovascular disease (CVD). Here the associations between water intake, chronic kidney disease (CKD) and CVD were examined in the general population. Methods: We conducted a cross-sectional analysis of the 2005-2006 National Health and Nutrition Examination Survey. Non-pregnant adults with an estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73 m2 who were not taking diuretics were included. Total water intake from foods and beverages was categorized as low (<2.0 l/day), moderate (2.0-4.3 l/day) and high (>4.3 l/day). We examined associations between low total water intake and CKD (eGFR 30-60 ml/min/1.73 m2) and self-reported CVD. Results: Of 3,427 adults (mean age 46 (range 20-84); mean eGFR 95 ml/min/1.73 m2 (range 30-161)), 13% had CKD and 18% had CVD. CKD was higher among those with the lowest (<2.0 l/day) vs. highest total water intake (>4.3 l/day) (adjusted odds ratio (OR) 2.52; 95% confidence interval (CI) 0.91-6.96). When stratified by intake of (1) plain water and (2) other beverages, CKD was associated with low intake of plain water: adjusted OR 2.36 (95% CI 1.10-5.06), but not other beverages: adjusted OR 0.87 (95% CI 0.30-2.50). There was no association between low water intake and CVD (adjusted OR 0.76; 95% CI 0.37-1.59). Conclusions: Our results provide additional evidence suggesting a potentially protective effect of higher total water intake, particularly plain water, on the kidney.

Arginine vasopressin (AVP) is an antidiuretic hormone that regulates thirst and water conservation in mammals. While essential for water regulation, AVP has vasoconstrictive effects and there is evidence that increased plasma levels can have negative effects on renal hemodynamics, blood pressure, and ventricular function [1,2,3,4,5,6,7]. AVP infusion increases proteinuria, renal plasma flow, and hyperfiltration, while administration of AVP antagonists reduces proteinuria and lowers blood pressure [1,3,8,9,10,11]. Although AVP is difficult to measure reliably in humans, a new assay for copeptin — a surrogate marker of AVP — shows promise as both a diagnostic and research tool. The BRAHMS copeptin assay (in combination with troponin T) may improve early diagnosis of myocardial infarction in the emergency room setting [6,12,13,14]. Copeptin positively associates with microalbuminuria in the general population [5,15], and higher levels predict faster renal decline in kidney transplant recipients [16].

Increased water intake suppresses plasma AVP [17,18] and exerts other hemodynamic effects [19]. In animal models, increased water intake has been shown to reduce proteinuria and slow renal progression [18,20]. In humans, several observational studies show that greater water intake may have a possible protective effect on renal and cardiovascular outcomes [21,22,23,24,25,26]. In a large Canadian cohort, lower urine volume at baseline predicted faster decline in estimated glomerular filtration rate (eGFR) over follow-up [22]. In the Adventist Health Study, cardiovascular mortality was inversely associated with water intake, although not with other fluids. Most recently, researchers identified chronic dehydration from heat stress as the most likely causal factor in a perplexing epidemic of chronic kidney disease (CKD) in Central America [24,25]. To examine the cross-sectional associations between water intake, CKD and cardiovascular disease (CVD) in the general population, we analyzed data from the National Health and Nutrition Examination Survey (NHANES). We also examined whether the relationship with total water intake differed for low vs. high intake of plain water vs. beverages other than plain water.


NHANES is an ongoing survey conducted in the USA by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention. Data from the 2005-2006 cohort were analyzed in the present study. NHANES participants (non-institutionalized US residents) are selected using a stratified, multistage national probability sampling design. Ethics approval for NHANES was obtained from the NCHS Research Ethics Review Board. Data collection for NHANES was approved by the NCHS Research Ethics Review Board. Analysis of de-identified data from the survey is exempt from the federal regulations for the protection of human research participants. Additional information about the 2005-2006 NHANES survey and methodology is available at

Data Collection and Measures

Participants completed an in-person structured interview, a physical examination (including height, weight and blood pressure measurements), and a computer-assisted 24-hour dietary recall. The dietary recall is a 5-step interview that includes multiple passes through the previous 24 h using standardized questions to help respondents recall and describe foods and beverages consumed [27,28]. Total water intake was estimated from all foods and beverages consumed within the previous 24 h. Water intake from beverages was grouped as follows: plain water (defined by the NCHS as tap water, water from a drinking fountain or water cooler, non-carbonated bottled water, and spring water); energy drinks, sugar- or artificially-sweetened drinks (carbonated or non-carbonated); alcoholic drinks; coffee or tea; fruit and vegetable juices, and milk, soymilk and other dairy drinks. In the absence of recommended daily intake values for fluid consumption based on physiological parameters and health outcomes, researchers often group respondents based on percentiles of total water intake [29,30,31,32]. As such, we defined low water intake as intake below the 20th percentile of total water intake (<2.0 l/day), moderate intake as intake between the 20th and 80th percentile (2.0-4.3 l/day), and high intake as intake greater than the 80th percentile of total water intake (>4.3 l/day). We applied the same algorithm to categorize total intake of (1) plain water and (2) beverages other than plain water. Kidney function was estimated from isotope dilution mass spectrometry (IDMS)-standardized serum creatinine values, and eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) [33]; CKD(stage III) was defined as eGFR between 30 and 59 ml/min/1.73 m2 (those with eGFR <30 were excluded) [34]. CVD was defined as a composite of a self-reported physician diagnosis of coronary heart disease, myocardial infarction, stroke, congestive heart failure, or angina pectoris. Hypertension was defined as average systolic/diastolic blood pressure ≥140/90 mm Hg or self-reported antihypertensive medication use. Diabetes was defined based on participant self-report of a physician diagnosis. Finally, participants were categorized as sedentary or active based on self-reported physical activity [35].

Inclusion/Exclusion Criteria

We included all adults aged 20-84 years with 1 day of complete and reliable dietary intake data. We excluded participants who were pregnant or had kidney cancer since these conditions may affect eGFR assessment. We also excluded participants taking lithium or diuretics because these medications may affect thirst and diuretics are often used when patients with heart failure are told to restrict their fluid intake (due to edema). Finally, we excluded those who reported weak or failing kidneys or treatment with dialysis in the past year and those who had an eGFR <30 ml/min/1.73 m2 because some patients with advanced kidney disease may be told to restrict fluid consumption (due to edema).

Statistical Analyses

All analyses were weighted using the NHANES dietary examination sample weights and adjusted for the complex sampling design using SAS Version 9.2 (SAS Institute, Inc., Cary, N.C., USA). Percentages are adjusted for survey sampling weights and are therefore discordant with percentages derived from raw frequencies; for this reason, weighted percentages with standard errors (SE) are presented, but raw frequencies are not [36]. Odds ratios (ORs) and 95% confidence intervals (CIs) for CKD and CVD were calculated using weighted logistic regression analysis; the reference group for all analyses was the high water intake group. All multivariable models included age (per year) and sex. In addition, the following variables were considered for inclusion: ethnicity, highest level of completed education, body mass index (BMI), smoking status, dietary sodium intake (mg/day), physical activity, hypertension, and diabetes. Models were reduced using backward elimination at α = 0.20 [37,38], unless elimination changed the exposure outcome association by more than 10% [38,39]. Separate analyses were run for low vs. high intake of (1) plain water and (2) beverages other than plain water. As recommended, we report 95% CIs, which incorporate the weighted variance estimates (rather than p values) to describe the precision of the estimates [40,41].

The 2005-2006 NHANES cycle included 4,400 respondents aged 20-84 years who completed the dietary interview and physical examination. After exclusions for pregnancy (n = 316), kidney cancer, weak or failing kidneys, dialysis, or eGFR <30 ml/min/1.73 m2 (n = 334), and lithium or diuretic medication use (n = 323), the final analytic sample included 3,427 participants. Sample characteristics, overall, and stratified by increasing water intake, are shown in table 1. Respondents were 50% female with a mean age of 46 (range 20-84) years; 13% were >65. Mean eGFR was 95 (range 30-161) ml/min/1.73 m2, and 13% had stage III CKD (eGFR 30-60 ml/min/1.73 m2).

Table 1

Sample characteristics, overall and stratified by daily total water intakea

Sample characteristics, overall and stratified by daily total water intakea
Sample characteristics, overall and stratified by daily total water intakea

Median daily water intake from all food and beverages was 2.9 liters, with 20% of total water coming from food. Median total water intake among those with low, moderate, and high intake was 1.6, 2.9, and 5.4 l/day, respectively (fig. 1). Plain water was the most common beverage consumed (median intake 1.0 l/day) followed by energy drinks and sugar- or artificially-sweetened drinks (carbonated or non-carbonated): 0.7 l/day; tea and coffee: 0.7 l/day; alcoholic beverages: 0.4 l/day; fruit and vegetable juice: 0.3 l/day, and milk, soy and/or other dairy drinks: 0.2 l/day. Median daily intake for each beverage category among those with low, moderate and high total water intake is shown in figure 1.

Fig. 1

Median daily water intake in liters (NHANES 2005-2006; n = 3,427).

Fig. 1

Median daily water intake in liters (NHANES 2005-2006; n = 3,427).

Close modal

Compared with those who had high water intake, those with low water intake were older (mean age 42 vs. 47), more likely to be female (35 vs. 69%), less likely to be non-Hispanic White (83 vs. 57%), less likely to have completed any education beyond high school (65 vs. 48%), less likely to be obese (32 vs. 28%), less likely to be current smokers (38 vs. 22%), more likely to be sedentary (50 vs. 76%), and to have hypertension (26 vs. 31%) or diabetes (8 vs. 11%) (table 1). Mean sodium intake was considerably higher in those with high vs. low water intake (4,697 vs. 2,595 mg/day).

The association between total water intake and reduced kidney function is shown in table 2. The prevalence of stage III CKD was highest among those with the lowest water intake (8.4%) and this decreased with increasing water intake: 3.7 and 1.3% among those with moderate and high water intake, respectively. After adjusting for age, sex, ethnicity, BMI, smoking status, sodium intake, hypertension, and diabetes, the adjusted OR for CKD among those with low vs. high water intake was 2.52 (95% CI 0.91-6.96). As shown in figure 2, the association between water intake and CKD was qualitatively different for (1) plain water and (2) other beverages: the adjusted OR for CKD in those with low vs. high intake of plain water was 2.36 (95% CI 1.10-5.06). When beverages other than plain water were considered, the adjusted OR for low vs. high intake was 0.87 (95% CI 0.30-2.50).

Table 2

Association between total water intake (from foods and beverages) and CKD

Association between total water intake (from foods and beverages) and CKD
Association between total water intake (from foods and beverages) and CKD
Fig. 2

Adjusted ORs and 95% CIs for CKD.

Fig. 2

Adjusted ORs and 95% CIs for CKD.

Close modal

CVD was reported by 18%. The association between water intake and CVD is shown in table 3. Compared with participants who had the highest water intake, those with lowest intake were more likely to report a history of coronary heart disease (1.7 vs. 3.3%), myocardial infarction (1.4 vs. 3.1%), stroke (1.8 vs. 2.6%), congestive heart failure (0.9 vs. 1.1%), and angina pectoris (1.3 vs. 1.6%). However, CVD was not associated with low water intake in multivariable analyses (adjusted OR 0.76; 95% CI 0.37-1.59). Results were similar when total water intake was restricted to plain water and to beverages other than plain water.

Table 3

Association between total water intake (from foods and beverages) and CVD

Association between total water intake (from foods and beverages) and CVD
Association between total water intake (from foods and beverages) and CVD

In this cross-sectional analysis of a representative sample of the US population, the prevalence of stage III CKD was highest among those with the lowest water intake. Interestingly, the association between daily water intake and CKD was only significant for low vs. high intake of plain water: OR 2.36 (95% CI 1.10-5.06), but not for low intake of beverages other than plain water: OR 0.87 (95% CI 0.30-2.50). No association was evident between low water intake and CVD: OR 0.76 (95% CI 0.37-1.59).

Although the relationship between hydration and health is controversial, with many unfounded claims in the popular media [42,43,44], our results are consistent with recent literature showing a specific beneficial effect of hydration on the kidney [18,20,22,23,24,25,45,46,47]. In particular, our results [22] complement a longitudinal analysis of a Canadian cohort in which lower urine volume predicted faster renal decline over follow-up. Clark et al. [22] measured 24-hour urine volume in over 2,000 adults who were free of CKD at baseline. Kidney function was measured annually for 6 years. For each increasing category of baseline urine volume (<1, 1-1.9, 2-2.9, and ≥3 l/day), the percent annual eGFR decline was progressively slower (1.3, 1.0, 0.8, and 0.5%, respectively; p = 0.02) — and those with the largest urine volumes were least likely to demonstrate rapid renal decline over follow-up. While Clark et al. did not collect data on the amount or type of fluid consumed, Strippoli et al. [23] conducted a cross-sectional analysis of an older Australian cohort (average age 66 years) and showed an inverse association between self-reported fluid intake and kidney function; however, they did not have data on plain water consumption and did not stratify by type beverage consumed. Participants with the highest quintile of fluid intake (>3.2 l/day) were significantly less likely to have CKD (eGFR <60 ml/min/1.73 m2) (OR 0.5; 95% CI 0.32-0.77). In contrast to these studies, in an observational study of patients with CKD, those with higher urine volumes had significantly faster renal decline [48]. This association may be partly explained by greater diuretic use among those with higher urine volumes. Also, because the kidneys concentrate urine less well as function declines, in patients with CKD, high urine volume could be the result, not the cause, of faster decline.

In addition to regulating fluid balance, the kidneys filter waste from the blood and may function more efficiently in the presence of an abundant fluid supply [49,50]. Higher water intake increases the clearance of sodium, urea and osmoles [51,52,53], and increased water intake is the most effective therapeutic measure to prevent kidney stones (and stones are also associated with loss of kidney function) [54,55,56,57]. Under conditions of low hydration, the kidneys produce more concentrated urine and there is some evidence that higher urine concentration may contribute to glomerular hyperfiltration and the development of albuminuria [8,15,46,58,59]. Exposure to chronic plasma volume depletion may make the kidneys more susceptible to subclinical injury, and accumulated damage from repeated insults may hasten the development of CKD [24]. This mechanism, exacerbated by heat stress, is believed to explain a recent epidemic of CKD among young male agricultural workers in Central America [24,25].

Despite the robust relationships between vasopressin, copeptin, and cardiovascular outcomes, the relationship between water intake and CVD is less clear. Water drinking may elicit a pressor response mediated through sympathetic nervous system activation [19]. There is some evidence that dehydration might contribute to increased blood viscosity [60,61], a known risk factor for ischemic heart disease and stroke [62,63]. However, several interventions have failed to reduce blood viscosity with greater fluid intake [60,61,64,65] — possibly because a benefit of greater water intake may not be realized in patients who are adequately hydrated, as appeared to be the case in one trial, where the baseline urine volume of patients was ∼1.6 l/day [65]. Few studies have evaluated the direct effect of water intake on cardiovascular outcomes, and these have produced equivocal results. In the Adventist Health Study, fatal coronary heart disease was significantly lower among participants who drank ≥5 cups of water daily compared with <2 cups [21], however no association was seen for high intakes of beverages other than water. In a Dutch cohort, neither total fluid intake nor plain water intake predicted fatal ischemic heart disease or stroke over 10 years of follow-up [66], however another prospective study found a significantly reduced risk of stroke recurrence among patients whose total self-reported water intake was >2 l/day compared with ≤2 l/day [26].

In the present study and others, the association between water intake and renal and vascular outcomes appears to be modified by source of water, where a beneficial effect is seen with greater intake of plain water, but not other beverages [21,67,68,69]. On the one hand, greater intake of plain water may be a marker for a healthier lifestyle. In a detailed dietary analysis of NHANES data by Kant et al. [28], plain water intake was positively correlated with education and fiber intake, and inversely correlated with age and sugar intake. The direction of these relationships reversed when other fluids were considered, and a positive correlation was seen between smoking and intake of other fluids. Despite this potential for confounding, a positive, causal effect of increased water consumption on kidney function is supported by several highly controlled studies of 5/6 nephrectomized rats, which show a consistent benefit of high water intake on preserving kidney function [18,20,45,46,47]. Even if increased hydration does in truth protect the kidney, any beneficial effect may be offset if total fluid consumption comes largely from sugar-sweetened beverages (usually sweetened with high-fructose corn syrup), which has been associated with the metabolic syndrome — and there is some evidence that fructose itself can cause kidney damage, perhaps by raising levels of uric acid [67,70,71,72]. This is supported by data from large observational studies that link high intake of sugar-sweetened beverages (≥2 cups/day) to albuminuria (OR 1.4; 95% CI 1.1-1.7), CKD (OR 2.3; 95% CI 1.4-3.7), and coronary heart disease (relative risk 1.4; 95% CI 1.1-1.69) [67,68,69].

Because this study was a cross-sectional analysis of observational data, conclusions about causality are not possible. Also, a 24-hour dietary recall may not accurately capture average long-term diet. Nonetheless, the 5-step multiple-pass dietary survey used in NHANES has been extensively studied and validated and is the most accurate method of dietary assessment for large population-based studies [27,73,74]. Moreover, our results are consistent with a diverse body of literature showing a beneficial effect of higher water intake on kidney function. We analyzed over 3,000 free-living adults in a nationally representative population in the USA. To minimize the potential for reverse causality, we also excluded those with advanced kidney disease (eGFR <30 ml/min/1.73 m2) and those taking diuretics. Whereas CKD was defined using an objective measure of kidney function, CVD was defined based on self-reported physician diagnosis. Even though the sensitivity and specificity of self-reported cardiovascular outcomes are reasonably good, ranging from 66 to 90% [75,76,77] and from 98 to 99% [75,77], respectively, outcome misclassification is likely, and this could have attenuated the association with this outcome. Although our results support a beneficial effect of higher water intake on kidney function, aggressive fluid loading should be avoided because of the attendant risk for hyponatremia [78,79].

Our analysis of a representative sample of the US population adds to a diverse body of literature showing a protective effect of higher water intake (particularly plain water) on the kidney. While our primary analysis considered total water intake from all foods and beverages combined, sensitivity analyses showed that CKD was inversely related to higher intake of plain water, but not other beverages, which is supported by other studies [21,67,68,69]. Taken together, these findings are provocative, however evidence from a large, well-designed randomized controlled trial is needed to determine if higher water intake can truly protect the kidney and slow renal decline.

The present results have not been published previously in whole or part. Dr. W. Clark has received consulting fees or honorarium and support to travel to meetings from Danone Research.

Representatives of Danone Research provided funds for this analysis of publicly available data from the 2005−2006 NHANES. The sponsor had no direct role in the data collection or statistical analysis.

Torres VE: Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int 2009;76:925-928.
Edwards RM, Trizna W, Kinter LB: Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989;256:F274-F278.
Perico N, Zoja C, Corna D, Rottoli D, Gaspari F, Haskell L, Remuzzi G: V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009;76:960-967.
Luft FC: Vasopressin, urine concentration, and hypertension: a new perspective on an old story. Clin J Am Soc Nephrol 2007;2:196-197.
Cirillo M: Determinants of kidney dysfunction: is vasopressin a new player in the arena? Kidney Int 2010;77:5-6.
Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction. Circulation 2007;115:2103-2110.
Goldsmith SR: Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am J Med 2006;119:S93-S96.
Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, Bankir L: Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003;18:497-506.
Bouby N, Hassler C, Bankir L: Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 1999;65:991-1004.
Okada H, Suzuki H, Kanno Y, Yamamura Y, Saruta T: Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Clin Sci 1994;86:399-404.
Bolignano D, Zoccali C: Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hypertens 2010;19:499-504.
Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T: Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-68.
Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S: Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096-2106.
National Institute for Health and Clinical Excellence: BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain. National Health Service, United Kingdom 2012.
Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010;77:29-36.
Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009;88:561-567.
Shore AC, Markandu ND, Sagnella GA, Singer DR, Forsling ML, Buckley MG, Sugden AL, MacGregor GA: Endocrine and renal response to water loading and water restriction in normal man. Clin Sci (Lond) 1988;75:171-177.
Bouby N, Bachmann S, Bichet D, Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990;258:F973.
May M, Jordan J: The osmopressor response to water drinking. Am J Physiol Regul Integr Comp Physiol 2011;300:R40-R46.
Sugiura T, Yamauchi A, Kitamura H, Matsuoka Y, Horio M, Imai E, Hori M: High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-β. Kidney Int 1999;55:1800-1810.
Chan J, Knutsen SF, Blix GG, Lee JW, Fraser GE: Water, other fluids, and fatal coronary heart disease. Am J Epidemiol 2002;155:827-833.
Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, Garg AX: Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011;6:2634-2641.
Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P: Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton) 2011;16:326-334.
Brooks DR, Ramirez-Rubio O, Amador JJ: CKD in Central America: a hot issue. Am J Kidney Dis 2012;59:481-484.
Peraza S, Wesseling C, Aragon A, Leiva R, Garcia-Trabanino RA, Torres C, Jakobsson K, Elinder CG, Hogstedt C: Decreased kidney function among agricultural workers in El Salvador. Am J Kidney Dis 2012;59:531-540.
Mucke S, Grotemeyer KH, Stahlhut L, Husstedt IW, Evers S: The influence of fluid intake on stroke recurrence - a prospective study. J Neurol Sci 2012;315:82-85.
Moshfegh AJ, Rhodes DG, Baer DJ, Murayi T, Clemens JC, Rumpler WV, Paul DR, Sebastian RS, Kuczynski KJ, Ingwersen LA, Staples RC, Cleveland LE: The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes. Am J Clin Nutr 2008;88:324-332.
Kant AK, Graubard BI, Atchison EA: Intakes of plain water, moisture in foods and beverages, and total water in the adult US population-nutritional, meal pattern, and body weight correlates: National Health and Nutrition Examination Surveys 1999-2006. Am J Clin Nutr 2009;90:655-663.
Armstrong LE, Pumerantz AC, Fiala KA, Roti MW, Kavouras SA, Casa DJ, Maresh CM: Human hydration indices: acute and longitudinal reference values. Int J Sport Nutr Exerc Metab 2010;20:145-153.
Armstrong LE, Johnson EC, Munoz CX, Swokla B, Le BL, Jimenez L, Casa DJ, Maresh CM: Hydration biomarkers and dietary fluid consumption of women. J Acad Nutr Diet 2012;112:1056-1061.
De Koning L, Malik VS, Rimm EB, Willett WC, Hu FB: Sugar-sweetened and artificially sweetened beverage consumption and risk of type 2 diabetes in men. Am J Clin Nutr 2011;93:1321-1327.
Institute of Medicine (US) Food and Nutrition Board: Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington, National Academy Press, 2005.
Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS: Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307:1941-1951.
Vassalotti JA, Stevens LA, Levey AS: Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169.
Tannenbaum SL: An investigation into equations for estimating water requirements and the development of new equations for predicting total water intake. 2011. FIU Electronic Theses and Dissertations.
National Center for Health Statistics. Analytic and Reporting Guidelines for the National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention. 8-8-2012.
Mickey RM, Greenland S: The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-137.
Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-936.
Greenland S, Rothman K: Introduction to stratified analysis; in Rothman K, Greenland S (eds): Modern Epidemiology, ed 2. Philadelphia, Lippincott-Raven, 1998, pp 253-279.
Gardner MJ, Altman DG: Confidence intervals rather than p values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986;292:746-750.
Vandenbroucke JP, von EE, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-W194.
Delamothe T: Water, water, everywhere. BMJ 2012;345.
Vreeman RC, Carroll AE: Medical myths. BMJ 2007;335:1288-1289.
Lette F, Dwyer JP: The fluid craze. Lancet 2008;372:782.
Bankir L, Bouby N, Trinh-Trang-Tan MM: Vasopressin-dependent kidney hypertrophy: role of urinary concentration in protein-induced hypertrophy and in the progression of chronic renal failure. Am J Kidney Dis 1991;17:661-665.
Bouby N, Ahloulay M, Nsegbe E, Dechaux M, Schmitt F, Bankir L: Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996;7:842-851.
Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17:2220-2227.
Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S: High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003;41:962-971.
Nicolaidis S: Physiology of thirst; in Arnaud MJ (ed): Hydration throughout Life. Montrouge, Libbey Eurotext, 1998, pp 3-9.
Berl T: Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 2008;19:1076-1078.
Pitts RF: Physiology of the Kidney and Body Fluids: an Introductory Text. Chicago, Year Book Medical Publishers, 1974.
Negoianu D, Goldfarb S: Just add water. J Am Soc Nephrol 2008;19:1041-1043.
Anastasio P, Cirillo M, Spitali L, Frangiosa A, Pollastro RM, De Santo NG: Level of hydration and renal function in healthy humans. Kidney Int 2001;60:748-756.
Siener R, Hesse A: Fluid intake and epidemiology of urolithiasis. Eur J Clin Nutr 2003;57:S47-S51.
Curhan GC, Willett WC, Speizer FE, Stampfer MJ: Beverage use and risk for kidney stones in women. Ann Intern Med 1998;128:534-540.
Consensus Conference: Prevention and treatment of kidney stones. JAMA 1988;260:977-981.
Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S, Klarenbach SW, Curhan GC, Tonelli M: Kidney stones and kidney function loss: a cohort study. BMJ 2012;345.
Bankir L, Yang B: New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism. Kidney Int 2012;81:1179-1198.
Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM, Bankir L: Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci USA 1999;96:10397-10402.
Okamura K, Washimi Y, Endo H, Tokuda H, Shiga Y, Miura H, Nojiri Y: Can high fluid intake prevent cerebral and myocardial infarction? Systematic review (in Japanese). Nippon Ronen Igakkai Zasshi 2005;42:557.
Kurabayashi H, Kubota K, Tamura J, Shirakura T: A glass of water at midnight for possible prevention of cerebral infarction. Stroke 1991;22:1326-1327.
Lee AJ, Mowbray PI, Lowe GD, Rumley A, Fowkes FG, Allan PL: Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 1998;97:1467-1473.
Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG: Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997;96:168-173.
Sugaya K, Nishijima S, Oda M, Miyazato M, Ogawa Y: Change of blood viscosity and urinary frequency by high water intake. Int J Urol 2007;14:470-472.
Tonstad S, Klemsdal TO, Landaas S, Hoieggen A: No effect of increased water intake on blood viscosity and cardiovascular risk factors. Br J Nutr 2006;96:993-996.
Leurs LJ, Schouten LJ, Goldbohm RA, van den Brandt PA: Total fluid and specific beverage intake and mortality due to IHD and stroke in the Netherlands Cohort Study. Br J Nutr 2010;104:1212.
Shoham DA, Durazo-Arvizu R, Kramer H, Luke A, Vupputuri S, Kshirsagar A, Cooper RS: Sugary soda consumption and albuminuria: results from the National Health and Nutrition Examination Survey, 1999-2004. PLoS One 2008;3:e3431.
Saldana TM, Basso O, Darden R, Sandler DP: Carbonated beverages and chronic kidney disease. Epidemiology 2007;18:501.
Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB: Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr 2009;89:1037-1042.
Nakagawa T, Tuttle KR, Short RA, Johnson RJ: Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005;1:80-86.
Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol 2006;290:F625-F631.
Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, Gersch MS, Benner S, Sanchez-Lozada LG: Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007;86:899-906.
Conway JM, Ingwersen LA, Vinyard BT, Moshfegh AJ: Effectiveness of the US Department of Agriculture 5-step multiple-pass method in assessing food intake in obese and non-obese women. Am J Clin Nutr 2003;77:1171-1178.
Johnson RK: Dietary intake - how do we measure what people are really eating? Obes Res 2002;10:63S-68S.
Engstad T, Bonaa KH, Viitanen M: Validity of self-reported stroke: the Tromso Study. Stroke 2000;31:1602-1607.
Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE: Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 1986;123:894-900.
Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ: Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096-1103.
Gardner J: Death by water intoxication. Mil Med 2002;167:432-434.
Noakes TD: Overconsumption of fluids by athletes. Br Med J 2003;327:113.
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (, applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.